Tiger Brokers

BUZZ-Nektar extends surge after promising eczema drug data

Reuters
Feb 11
BUZZ-Nektar extends surge after promising eczema drug data

** Nektar Therapeutics NKTR.O shares up 14.9% to $64.33, over two-month high on Weds, adding to big gain in prior session after its eczema drug showed promise

** NKTR shares surged 51% on Tues after co earlier in the day said rezpegaldesleukin showed year-long benefit

** After the bell Tues, NKTR commenced $300 mln offering consisting of stock and pre-funded warrants in part to fund Phase 3 trials for rezpegaldesleukin

** Jefferies, TD Cowen and Piper Sandler joint bookrunners

** BTIG on Tues said after the data NKTR remains one of its 1H26 top picks and hiked its PT from $118 to $151

** 7 of 8 analysts rate stock "strong buy" or "buy", 1 "hold"; median PT $115, per LSEG data

** With the move on Weds, NKTR shares up more than six-fold over the past 12 months

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10